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Clinical PerspectiveWhat Is New?Risk prediction is central to decision making for patients with advanced valvular heart disease; however, the performance of clinical predictive models in external validations is often substantially worse than expected based on derivation data set performance.What Are the Clinical Implications?Isolated external validations appear insufficient to broadly understand the performance of valvular heart disease clinical predictive models.There are clinical predictive models for surgical valvular heart disease interventions that perform well across multiple external validations.The trustworthiness of transcatheter aortic valve replacement predictions is largely unknown as these models have not been widely tested in external validations.

Introduction {#jah34436-sec-0008}
============

Treatments for patients with advanced valvular heart disease (VHD) are increasingly offered to patients with advanced age and elevated pre‐procedural risk.[1](#jah34436-bib-0001){ref-type="ref"}, [2](#jah34436-bib-0002){ref-type="ref"}, [3](#jah34436-bib-0003){ref-type="ref"} Clinical predictive models (CPMs) have assumed a central role in clinical decision making and current guidelines link VHD treatment decisions to predicted risk.[4](#jah34436-bib-0004){ref-type="ref"}, [5](#jah34436-bib-0005){ref-type="ref"}, [6](#jah34436-bib-0006){ref-type="ref"} CPMs can potentially enhance shared decision making,[7](#jah34436-bib-0007){ref-type="ref"}, [8](#jah34436-bib-0008){ref-type="ref"} when they perform well and are appropriately matched to the correct decisional context, though there remain major questions about how well CPMs for patients with VHD perform in external validations.

It is well recognized that many of the best known (and most widely used) CPMs for VHD were derived on patients receiving surgical interventions[9](#jah34436-bib-0009){ref-type="ref"}, [10](#jah34436-bib-0010){ref-type="ref"} and do not accurately predict outcomes for patients treated with percutaneous interventions,[11](#jah34436-bib-0011){ref-type="ref"} though they continue to be used for this purpose. While there are newer efforts to create CPMs specific to percutaneous valve interventions, the relative performance of these models and their performances in external validations remains largely unknown. Generally, the performance of CPMs has often been underreported and incompletely assessed[12](#jah34436-bib-0012){ref-type="ref"} and since CPMs that perform poorly can yield misleading predictions that motivate harmful decision making,[13](#jah34436-bib-0013){ref-type="ref"} it is essential that clinicians understand CPM performance before leveraging outputs to inform decisions. This is especially important for VHD treatment decisions, given the importance of these tools.

Here, using the Tufts PACE (Predictive Analytics and Comparative Effectiveness) CPM Registry, we describe the available CPMs for patients with VHD treated with percutaneous or surgical interventions. This analysis focuses on comparative model performance during external validations.

Methods {#jah34436-sec-0009}
=======

General Approach {#jah34436-sec-0010}
----------------

The data that support the findings of this study are available from the corresponding author upon reasonable request. This study analyzed data from the Tufts PACE (Predictive Analytics and Comparative Effectiveness) CPM Registry, a database created to describe the CPM literature for patients at risk for and with known cardiovascular disease. The registry, which is free and available to the public at <http://pace.tuftsmedicalcenter.org/cpm>, encompasses a field synopsis of CPMs for patients with VHD. The methods have been previously reported.[12](#jah34436-bib-0012){ref-type="ref"} Briefly, we had previously searched PubMed for English‐language articles containing CPMs for cardiovascular disease published from January 1990 through 2015. We extended the search for VHD CPMs to January 2017 to include more recent CPM development (Table [S1](#jah34436-sup-0001){ref-type="supplementary-material"}, Figure [S1](#jah34436-sup-0001){ref-type="supplementary-material"}). Citations were reviewed to confirm completeness of our review. All citations and data fields were extracted in duplicate to ensure accuracy. Discrepancies were discussed until consensus was achieved.

For inclusion in the registry, articles had to meet the following criteria: (1) develop a CPM as a primary aim, (2) contain a model predicting the development of a specified clinical diagnosis (diagnostic models) or the probability of developing a clinical outcome (prognostic models), (3) contain at least 2 outcome predictors, and (4) present enough information to estimate the probability for an individual patient. Articles were excluded if they did not provide enough information to predict a patient\'s risk or if the described models predicted surrogate outcomes. We also excluded non‐English reports, pharmacology reports, cost‐effectiveness models, decision‐analysis models, systematic reviews, and editorials.

Model Selection {#jah34436-sec-0011}
---------------

This report focuses on CPMs predicting outcomes for patients with VHD. CPMs predicting natural history outcomes and outcomes after surgical and percutaneous procedures were included. CPMs were grouped based on underlying valve pathology and procedure. CPMs were also included if they were derived on cardiac surgery cohorts where at least 50% of patients received treatment for VHD. CPMs derived exclusively on coronary artery bypass populations were excluded.

CPM Reporting {#jah34436-sec-0012}
-------------

Information was extracted on CPM derivation and reporting. Collected fields included: index clinical condition, predicted outcome, timeframe of prediction, sample size, cohort size, and number of events. We calculated the events per variable (EPV) based on the number of variables included in the model. We also extracted information on modeling method and performance with specific attention to reporting of discrimination and calibration (Table [S2](#jah34436-sup-0001){ref-type="supplementary-material"}).

Validation Search {#jah34436-sec-0013}
-----------------

Citations for each CPM article through September 2017 were identified using Scopus and reviewed for inclusion as external validations. An external validation was defined as any evaluation of CPM performance (assessment of either discrimination or calibration) on a data set distinct from the derivation data set.[14](#jah34436-bib-0014){ref-type="ref"} External validations included validations that were done on the same cohort but temporally or geographically distinct from the derivation cohort or on an entirely separate cohort. Each validation citation was reviewed by 2 investigators for inclusion and discrepancies were reviewed with an additional investigator to arrive at consensus.

Validation Reporting {#jah34436-sec-0014}
--------------------

Information on validation reporting was extracted, including sample size, continent of study, number of events, and reporting of measures of discrimination and calibration (Table [S3](#jah34436-sup-0001){ref-type="supplementary-material"}). The validation performance analysis focused on whether CPM discrimination changed when compared with that seen in the derivation population. Because the c‐statistic ranges from 0.5 (no discriminatory ability) to 1.0 (perfect discrimination), it has been rescaled as Somer\'s D statistic[15](#jah34436-bib-0015){ref-type="ref"} (2×(c−0.5)) so that discrimination ranges from 0 (no discrimination) to 1.0 (perfect discrimination). We describe changes on this scale because it more intuitively reflects the true changes in discriminatory power. The percentage change in discrimination \[(Validation AUC−0.5)−(Derivation AUC−0.5)/(Derivation AUC−0.5)×100\] is presented. We also document whether validations include any assessment of CPM calibration. There is currently no literature standard for assessing calibration. Given this lack of consistency and interpretability, we have only reported on whether this dimension of performance was assessed. Calibration assessment included any comparison of observed versus expected outcomes. Examples include a Hosmer‐Lemeshow statistic or calibration plot. For this study we also included measures of global fit, where overall observed event rates are compared with predicted rates (ie, calibration‐in‐the‐large).

Relatedness {#jah34436-sec-0015}
-----------

To assess the similarity between the derivation population and the validation population for each validation, we created a relatedness rubric to divide validations into 2 categories---"related" and "distantly related." The rubric contained 3 domains: (1) type of intervention (ie, percutaneous or surgical), (2) percentage of the population undergoing isolated valve procedures (as opposed to valve procedures in combination with revascularization), and (3) calendar years of enrollment. We considered a validation population to be "related" if all of the following criteria were met: (1) same type of intervention (eg, both surgical populations), (2) ± 10% absolute difference in the proportion of isolated valve procedure (eg, derivation population was 100% isolated valve and validation population was 95% isolated valve), and (3) overlapping years of enrollment. Matches that did not meet all 3 criteria were deemed "distantly related."

Results {#jah34436-sec-0016}
=======

VHD CPMs {#jah34436-sec-0017}
--------

We identified 49 CPMs predicting clinical outcomes for patients with VHD, which were cited a total of 1296 times (Table [1](#jah34436-tbl-0001){ref-type="table"}, Table [S2](#jah34436-sup-0001){ref-type="supplementary-material"}).[7](#jah34436-bib-0007){ref-type="ref"}, [9](#jah34436-bib-0009){ref-type="ref"}, [16](#jah34436-bib-0016){ref-type="ref"}, [17](#jah34436-bib-0017){ref-type="ref"}, [18](#jah34436-bib-0018){ref-type="ref"}, [19](#jah34436-bib-0019){ref-type="ref"}, [20](#jah34436-bib-0020){ref-type="ref"}, [21](#jah34436-bib-0021){ref-type="ref"}, [22](#jah34436-bib-0022){ref-type="ref"}, [23](#jah34436-bib-0023){ref-type="ref"}, [24](#jah34436-bib-0024){ref-type="ref"}, [25](#jah34436-bib-0025){ref-type="ref"}, [26](#jah34436-bib-0026){ref-type="ref"}, [27](#jah34436-bib-0027){ref-type="ref"}, [28](#jah34436-bib-0028){ref-type="ref"}, [29](#jah34436-bib-0029){ref-type="ref"}, [30](#jah34436-bib-0030){ref-type="ref"}, [31](#jah34436-bib-0031){ref-type="ref"}, [32](#jah34436-bib-0032){ref-type="ref"}, [33](#jah34436-bib-0033){ref-type="ref"}, [34](#jah34436-bib-0034){ref-type="ref"}, [35](#jah34436-bib-0035){ref-type="ref"}, [36](#jah34436-bib-0036){ref-type="ref"}, [37](#jah34436-bib-0037){ref-type="ref"}, [38](#jah34436-bib-0038){ref-type="ref"}, [39](#jah34436-bib-0039){ref-type="ref"}, [40](#jah34436-bib-0040){ref-type="ref"}, [41](#jah34436-bib-0041){ref-type="ref"}, [42](#jah34436-bib-0042){ref-type="ref"}, [43](#jah34436-bib-0043){ref-type="ref"} Thirty‐four (69%) predict outcomes following surgical interventions, 12 (24%) predict outcomes following percutaneous interventions, and 3 (6%) predict outcomes in the absence of intervention (Table [2](#jah34436-tbl-0002){ref-type="table"}). Overall, the most commonly predicted outcomes were 30‐day mortality (n=14, 29%) and in‐hospital mortality (n=14, 29%). Twenty‐four models (46%) were derived from patients in North America, followed by 12 (23%) from Europe and 8 (15%) from Asia (Figure [1](#jah34436-fig-0001){ref-type="fig"}). The median derivation sample size was 4510 (interquartile range \[IQR\], 1087--18 686), median event rate was 8.3% (IQR, 4.5%--14.8%), and median EPV was 40 (IQR, 20--92) (Table [2](#jah34436-tbl-0002){ref-type="table"}). The median number of covariates was 10 (IQR, 7--19).

###### 

De Novo VHD CPMs Overview

  Author, Model Name                                                                                   Publication, y   Valve                       Standardized Type of Intervention   Outcome                    Model Method                      C‐Statistic   Calibration Measure                                         Externally Validated?
  ---------------------------------------------------------------------------------------------------- ---------------- --------------------------- ----------------------------------- -------------------------- --------------------------------- ------------- ----------------------------------------------------------- -----------------------
  Isolated valve                                                                                                                                                                                                                                                                                                               
  Edwards,[16](#jah34436-bib-0016){ref-type="ref"} STS (original) Isolated Valve                       2001             Aortic/Mitral               Surgery                             30 d operative mortality   Logistic regression               0.766         HL statistic, Calibration plot                              Yes
  Nowicki,[17](#jah34436-bib-0017){ref-type="ref"} NNE Aortic and Mitral Models                        2004             Aortic                      Surgery                             In‐hospital mortality      Logistic regression, score        0.75          HL statistic                                                Yes
  Mitral                                                                                               Surgery          In‐hospital mortality       Logistic regression, score          0.79                       HL statistic                      Yes                                                                       
  Kuduvalli,[18](#jah34436-bib-0018){ref-type="ref"} NWQIP                                             2007             Aortic                      Surgery                             In‐hospital mortality      Logistic regression, score        0.78          HL statistic                                                Yes
  Cruz‐Gonzalez,[19](#jah34436-bib-0019){ref-type="ref"} PMV Score                                     2009             Mitral                      Percutaneous                        Procedural success         Logistic regression, score        NR            HL statistic                                                Yes
  Monin[20](#jah34436-bib-0020){ref-type="ref"}                                                        2009             Aortic stenosis             Natural History                     Composite (Non‐MACE)       Logistic regression, score        0.90          HL statistic                                                Yes
  O\'Brien,[9](#jah34436-bib-0009){ref-type="ref"} STS (2009)---Composite AEs                          2009             Aortic/Mitral               Surgery                             Composite (Non‐MACE)       Logistic regression               0.721         None                                                        Yes
  O\'Brien,[9](#jah34436-bib-0009){ref-type="ref"} STS (2009)---DSWI                                   2009             Aortic/Mitral               Surgery                             DSWI                       Logistic regression               0.704         None                                                        Yes
  O\'Brien,[9](#jah34436-bib-0009){ref-type="ref"} STS (2009)---Mortality                              2009             Aortic/Mitral               Surgery                             30 d mortality             Logistic regression               0.805         None                                                        Yes
  O\'Brien,[9](#jah34436-bib-0009){ref-type="ref"} STS (2009)---Prolonged LOS                          2009             Aortic/Mitral               Surgery                             Prolonged LOS              Logistic regression               0.77          None                                                        Yes
  O\'Brien,[9](#jah34436-bib-0009){ref-type="ref"} STS (2009)---Prolonged Ventilation                  2009             Aortic/Mitral               Surgery                             Prolonged ventilation      Logistic regression               0.77          None                                                        Yes
  O\'Brien,[9](#jah34436-bib-0009){ref-type="ref"} STS (2009)---Renal Failure                          2009             Aortic/Mitral               Surgery                             Renal failure              Logistic regression               0.782         None                                                        Yes
  O\'Brien,[9](#jah34436-bib-0009){ref-type="ref"} STS (2009)---Reoperation                            2009             Aortic/Mitral               Surgery                             Reoperation                Logistic regression               0.643         None                                                        Yes
  O\'Brien,[9](#jah34436-bib-0009){ref-type="ref"} STS (2009)---Short LOS                              2009             Aortic/Mitral               Surgery                             Prolonged LOS              Logistic regression               0.738         None                                                        No
  O\'Brien,[9](#jah34436-bib-0009){ref-type="ref"} STS (2009)---Stroke                                 2009             Aortic/Mitral               Surgery                             Stroke                     Logistic regression               0.694         None                                                        Yes
  Guaragna,[21](#jah34436-bib-0021){ref-type="ref"} GuaragnaSCORE                                      2010             Aortic/Mitral               Surgery                             In‐hospital mortality      Logistic regression, score        0.82          HL statistic, Calibration plot                              Yes
  Guo[22](#jah34436-bib-0022){ref-type="ref"}                                                          2010             Aortic                      Surgery                             In‐hospital mortality      Logistic regression               NR            HL statistic                                                No
  Mitral                                                                                               Surgery          In‐hospital mortality       Logistic regression                 NR                         HL statistic                      No                                                                        
  Elmariah,[23](#jah34436-bib-0023){ref-type="ref"} CRRAC the AV Score                                 2011             Aortic                      Percutaneous                        30 d mortality             Cox regression, score             0.754         HL statistic                                                No
  Bouleti[24](#jah34436-bib-0024){ref-type="ref"}                                                      2012             Mitral                      Percutaneous                        Composite (MACE)           Cox regression, score             0.74          Calibration plot                                            No
  Cioffi[25](#jah34436-bib-0025){ref-type="ref"}                                                       2012             Aortic stenosis             Natural History                     Composite (MACE)           Cox regression, score             NR            None                                                        No
  Holme,[26](#jah34436-bib-0026){ref-type="ref"} SEAS Score                                            2012             Aortic stenosis             Natural History                     5 y mortality              Cox regression                    0.722         HL statistic, Calibration plot, Brier score                 No
  Kötting,[27](#jah34436-bib-0027){ref-type="ref"} German Aortic Valve Score                           2013             Aortic                      Percutaneous                        In‐Hospital Mortality      Logistic regression, score        0.808         HL statistic                                                Yes
  Arnold,[28](#jah34436-bib-0028){ref-type="ref"} 6 mo and 1 y Models                                  2014             Aortic stenosis             Percutaneous                        Composite (Non‐MACE)       Logistic regression               0.66          HL statistics, Calibration plot                             Yes
  Aortic stenosis                                                                                      Percutaneous     Composite (Non‐MACE)        Logistic regression                 0.66                       HL statistics, Calibration plot   Yes                                                                       
  Capodanno,[29](#jah34436-bib-0029){ref-type="ref"}  OBSERVANT Score                                  2014             Aortic stenosis             Percutaneous                        30 d mortality             Logistic regression, score        0.73          HL statistic, Calibration plot, Brier score                 Yes
  D\'Ascenzo,[30](#jah34436-bib-0030){ref-type="ref"} Survival Post‐TAVI (STT)---30 d and 1 y Models   2014             Aortic                      Percutaneous                        30 d mortality             Logistic regression, score        0.66          HL statistic                                                Yes
  Aortic                                                                                               Percutaneous     1 y mortality               Logistic regression, score          0.68                       HL statistic                      Yes                                                                       
  Iung[31](#jah34436-bib-0031){ref-type="ref"}                                                         2014             Aortic                      Percutaneous                        30 d mortality             Logistic regression, score        0.67          HL statistic, Calibration in the large, Calibration plot    No
  Debonnaire,[32](#jah34436-bib-0032){ref-type="ref"} TAVI2‐SCORe                                      2015             Aortic                      Percutaneous                        1 y mortality              Cox regression, score             0.715         HL statistic, Calibration in the large                      Yes
  Edwards[7](#jah34436-bib-0007){ref-type="ref"}                                                       2016             Aortic                      Percutaneous                        In‐hospital mortality      Logistic regression               0.67          HL statistics, Calibration in the large, Calibration plot   Yes
  Isolated or multiple valve                                                                                                                                                                                                                                                                                                   
  Koplan[33](#jah34436-bib-0033){ref-type="ref"}                                                       2003             All                         Surgery                             Pacemaker placement        Logistic regression, score        NR            None                                                        No
  Ambler[34](#jah34436-bib-0034){ref-type="ref"}                                                       2005             Aortic, mitral              Surgery                             In‐hospital mortality      Logistic regression, Score        0.77          HL statistic, Calibration plot                              Yes
  Xu[35](#jah34436-bib-0035){ref-type="ref"}                                                           2006             All                         Surgery                             Prolonged LOS              Logistic regression               0.81          Calibration in table form                                   No
  Hannan[36](#jah34436-bib-0036){ref-type="ref"}                                                       2007             Aortic, mitral              Surgery                             In‐hospital mortality      Logistic regression, Score        0.794         HL statistic, Calibration plot                              Yes
  Xu,[37](#jah34436-bib-0037){ref-type="ref"} Fuwai Score                                              2007             All                         Surgery                             Prolonged LOS              Logistic regression, Score        0.76          HL statistic, Calibration plot                              Yes
  Shi[38](#jah34436-bib-0038){ref-type="ref"}                                                          2010             Aortic, mitral              Surgery                             In‐hospital mortality      Logistic regression               0.7358        None                                                        No
  Ariyaratne,[39](#jah34436-bib-0039){ref-type="ref"} Aus‐AVR Score                                    2011             Aortic, mitral              Surgery                             30 d mortality             Logistic regression, Score        0.78          HL statistic, Calibration in the large                      Yes
  Nashef,[10](#jah34436-bib-0010){ref-type="ref"} EuroSCORE II                                         2012             All                         Surgery                             In‐hospital mortality      Logistic regression               0.8095        None                                                        Yes
  Hannan,[40](#jah34436-bib-0040){ref-type="ref"} NY Operative Mortality Risk Score                    2013             Aortic, mitral              Surgery                             30 d mortality             Logistic regression, Score        0.781         HL statistic                                                Yes
  Wang[41](#jah34436-bib-0041){ref-type="ref"}                                                         2013             All                         Surgery                             Prolonged ventilation      Logistic regression               0.789         HL statistic                                                No
  Zheng[42](#jah34436-bib-0042){ref-type="ref"}                                                        2013             Aortic, mitral              Surgery                             In‐hospital mortality      Logistic regression, Score        0.76          HL statistic, Chi‐square statistic, Calibration plot        No
  Multiple valve                                                                                                                                                                                                                                                                                                               
  Guo[22](#jah34436-bib-0022){ref-type="ref"}                                                          2010             Aortic, mitral              Surgery                             In‐hospital mortality      Logistic regression               NR            HL statistic                                                No
  Rankin,[43](#jah34436-bib-0043){ref-type="ref"} AM Preop                                             2013             Aortic, mitral              Surgery                             30 d mortality             Logistic regression               NR            Calibration plot                                            Yes
  Rankin,[43](#jah34436-bib-0043){ref-type="ref"} MT Preop                                             2013             mitral, tricuspid           Surgery                             30 d mortality             Logistic regression               NR            Calibration plot                                            Yes
  Rankin,[43](#jah34436-bib-0043){ref-type="ref"} AMT Preop                                            2013             Aortic, mitral, tricuspid   Surgery                             30 d mortality             Logistic regression               NR            Calibration plot                                            Yes
  Rankin,[43](#jah34436-bib-0043){ref-type="ref"} AM Preop + Intraop                                   2013             Aortic, mitral              Surgery                             30 d mortality             Logistic regression               NR            Calibration plot                                            Yes
  Rankin,[43](#jah34436-bib-0043){ref-type="ref"} MT Preop + Intraop                                   2013             Mitral, tricuspid           Surgery                             30 d mortality             Logistic regression               NR            Calibration plot                                            Yes
  Rankin,[43](#jah34436-bib-0043){ref-type="ref"} AMT Preop + Intraop                                  2013             Aortic, mitral, tricuspid   Surgery                             30 d mortality             Logistic regression               NR            Calibration plot                                            Yes

AEs indicates adverse events; AM, aortic, mitral ; AMT, aortic, mitral, tricuspid; AV, aortic valvuloplasty; Aus‐AVR, Australian aortic valve replacement; CRRAC, critical status, renal dysfunction, right atrial pressure, and cardiac output; DSWI, deep sternal wound infections; EuroSCORE, European System for Cardiac Operative Risk Evaluation; HL, Hosmer‐Lemeshow; LOS, length of stay; MACE, major adverse cardiovascular events; MT, mitral, tricuspid; NNE, Northern New England; NR, not reported; NWQIP, North West Quality Improvement Programme in Cardiac Interventions; NY, New York; OBSERVANT, Observational Study of Appropriateness, Efficacy and Effectiveness of AVR‐TAVR Procedures for the Treatment of Severe Symptomatic Aortic Stenosis; PMV, percutaneous mitral valvuloplasty; SEAS, Simvastatin and Ezetimibe in Aortic Stenosis; STS, Society of Thoracic Surgeons; STT, Survival posT‐TAVI; TAVI, transcatheter aortic valve implantation; TAVR, Transcatheter Aortic Valve Replacement.

###### 

Reported Characteristics of De Novo Valvular Heart Disease CPMs

  Characteristic[a](#jah34436-note-0003){ref-type="fn"}      Overall (n=49)        Surgical (n=34)         Percutaneous (n=12)   Natural History (n=3)
  ---------------------------------------------------------- --------------------- ----------------------- --------------------- -----------------------
  Publication range[b](#jah34436-note-0004){ref-type="fn"}   2001 to 2016          2001 to 2013            2009 to 2016          2009 to 2012
  Age, y                                                     69 (61--79)           65 (58--70)             82 (82--83)           68 (67--70)
  Sample size                                                4510 (1087--18 686)   12 079 (3125--92 563)   1160 (752--2241)      772 (440--1169)
  Event rate                                                 0.08 (0.05--0.15)     0.07 (0.04--0.11)       0.14 (0.06--0.37)     0.35 (0.23--0.47)
  Events per variable                                        40 (20--92)           46 (25--110)            42 (18--81)           11 (10--45)
  C‐statistic                                                0.76 (0.72--0.78)     0.77 (0.75--0.79)       0.68 (0.67--0.74)     0.81 (0.77--0.86)
  \% Externally validated                                    71.4                  73.5                    83.3                  33.3

CPM indicates clinical predictive models.

Values are reported as median (interquartile range), unless otherwise specified.

De novo CPM search spans January 1, 1990 to January 1, 2017.

![Geography of derivation and validation cohorts. Country of origin for derivation (**A**) and validation (**B**) populations. Maps created in Tableau Public.](JAH3-8-e011972-g001){#jah34436-fig-0001}

Among models that reported a c‐statistic (n=37, 76%), the overall median ROC was 0.76 (IQR, 0.72--0.78) (Table [2](#jah34436-tbl-0002){ref-type="table"}). When stratified by intervention type, the median c‐statistic was 0.77 (IQR, 0.75--0.79) for CPMs predicting outcomes following surgical interventions, 0.68 (IQR, 0.67--0.74) for CPMs for percutaneous interventions, and 0.81 (IQR, 0.77--0.86) for CPMs predicting outcomes in the absence of intervention (Table [2](#jah34436-tbl-0002){ref-type="table"}).

CPMs for Isolated Valve Disease {#jah34436-sec-0018}
-------------------------------

There are 31 CPMs for isolated valve disease. Sixteen (52%) predict outcomes following surgical intervention and 12 (39%) predict outcomes following percutaneous interventions (transcatheter aortic valve replacement \[TAVR\], balloon aortic valvuloplasty, and percutaneous mitral balloon valvuloplasty). Three CPMs (10%) predict outcomes for patients with aortic stenosis in the absence of intervention. The median derivation sample size was 2552 (IQR, 1064--108 410) and the median age was 70 (IQR, 64--82). The median number of events was 360 (IQR, 104--2021) and the median EPV was 55 (IQR, 18--112). The median event rate was 10% (IQR, 4.6%--18.3%). For the 27 (87%) models reporting discrimination, the median c‐statistic was 0.74 (IQR, 0.69--0.78).

CPMs for Isolated or Multiple Valve Disease {#jah34436-sec-0019}
-------------------------------------------

There are 11 CPMs that predict outcomes for patients undergoing either single or multiple valve surgical procedures. The median derivation sample size was 3544 (IQR, 2297--12 079) and the median age was 60 (IQR, 54--65). The median number of events was 303 (IQR, 139--507) and the median EPV was 26 (IQR, 20--40). The median event rate was 5.1% (IQR, 4.1%--9.5%). For the 10 (91%) models reporting discrimination, the median c‐statistic was 0.78 (IQR, 0.76--0.79).

CPMs for Multiple Valve Disease {#jah34436-sec-0020}
-------------------------------

There are 7 CPMs that predict outcomes specifically for multiple valve surgical interventions. These CPMs include the Society of Thoracic Surgeons (STS) Multi‐Valve Risk Models[43](#jah34436-bib-0043){ref-type="ref"} and the median derivation sample size was 18 686 (IQR, 4510--22 861). The median number of events was 1420 (IQR, 591--1981) and the median EPV was 71 (IQR, 48--92). Median age was 70 (IQR, 70--71). The median event rate was 9.4% (IQR, 7.6%--11.3%). Median number of covariates was 20 (IQR, 14--23).

CPMs for Percutaneous VHD Interventions {#jah34436-sec-0021}
---------------------------------------

Since 2009, there have been 12 CPMs presented that predict outcomes following percutaneous VHD interventions. Two models predict outcomes following mitral percutaneous mitral balloon valvuloplasty.[24](#jah34436-bib-0024){ref-type="ref"}, [44](#jah34436-bib-0044){ref-type="ref"} There were 9 CPMs that predict outcomes following TAVR with a median derivation sample size of 2130 (IQR, 10 642 552). The median age of patients in the TAVR CPMs was 82 (IQR, 82--83). TAVR CPMs had a median number of events of 253 (IQR, 80--704) and the median EPV was 28 (IQR, 20--70). The median event rate was 9.9% (IQR, 5.6%--15.7%). All of the CPMs predicting outcomes following TAVR reported discrimination with a median c‐statistic of 0.67 (IQR, 0.66--0.72).

External Validations {#jah34436-sec-0022}
--------------------

Two hundred and four external validations of these CPMs were identified, of which 190 (93%) report a c‐statistic. Overall, 35 (71%) of the VHD CPMs have been externally validated and 20 (37%) have been externally validated more than once. External validations were most commonly done in cohorts of patients from Europe (n=93, 46%), Asia (n=38, 19%), and North America (n=37, 18%) (Figure [1](#jah34436-fig-0001){ref-type="fig"}). Fifty‐three (26%) validations were performed on populations from the same continent as the derivation population, with a median c‐statistic of 0.71 (IQR, 0.66--0.77). Seventy‐one (35%) were done on populations from a different continent, with a median c‐statistic of 0.68 (IQR, 0.64--0.73). External validations overall had a median c‐statistic of 0.71 (IQR, 0.65-- 0.77) (Table [3](#jah34436-tbl-0003){ref-type="table"}). For the models that were externally validated, we noted an overall median percentage change in discrimination of −27.1% (IQR, −49.4--−5.7). Just under two‐thirds of validations (n=129) demonstrate at least a 10% relative decline in discriminatory power, and 18 (9%) showed a decline of \>80%. Thirty‐three (16%) validations showed CPM discrimination at or above that seen in the derivation cohort.

###### 

Reported Characteristics of Valvular Heart Disease External Validations[c](#jah34436-note-0008){ref-type="fn"}

  Characteristic[a](#jah34436-note-0006){ref-type="fn"}   Overall (n=204)[b](#jah34436-note-0007){ref-type="fn"}   Surgical (n=131)    Percutaneous (n=70)
  ------------------------------------------------------- -------------------------------------------------------- ------------------- ---------------------
  Sample size                                             450 (249--1495)                                          809 (407--3306)     304 (180--453)
  Number of events                                        38 (15--95)                                              48 (14--119)        38 (15--56)
  Event rate                                              0.06 (0.03--0.12)                                        0.04 (0.03--0.07)   0.11 (0.08--0.17)
  \% Men                                                  53 (47--62)                                              57 (53--66)         47 (43--52)
  C‐statistic                                             0.71 (0.65--0.77)                                        0.74 (0.70--0.79)   0.63 (0.57--0.68)

Values are reported as median (interquartile range).

Validations done on populations treated with surgical and percutaneous interventions that did not disaggregate results (n=2) are only included in the overall count.

Validation search includes citations through September 8, 2017.

The distribution of number of validations was skewed towards a small number of CPMs. Two CPMs (EuroSCORE II and STS \[2009\] Models[9](#jah34436-bib-0009){ref-type="ref"}) accounted for 73% of the external validations. EuroSCORE II has been validated 78 times across 5 continents (Table [4](#jah34436-tbl-0004){ref-type="table"}). Validation c‐statistics ranged from 0.50 to 0.95 with a median percentage change of −23.4% (range −100%--+46.7%). For the STS (2009) Models, validation c‐statistics ranged from 0.50 to 0.86 (Table [5](#jah34436-tbl-0005){ref-type="table"}). The median percentage change was −31.8% and ranged from −100% to +18%. The STS (2009) Models have been validated 70 times across 5 continents.

###### 

EuroSCORE II Population Compared With External Validation Populations, Stratified by Relatedness

  Statistic[a](#jah34436-note-0009){ref-type="fn"}                     EuroSCORE II             Validation Populations[b](#jah34436-note-0010){ref-type="fn"}, [c](#jah34436-note-0011){ref-type="fn"}   
  -------------------------------------------------------------------- ------------------------ -------------------------------------------------------------------------------------------------------- ---------------------
  Total patients (n)                                                   16 828                   14 382                                                                                                   98 744
  Total validations (n)                                                NA                       5                                                                                                        73
  Age, y                                                               Mean (SD): 64.6 (12.5)   63.4 (62.7--67.0)                                                                                        67.1 (61.1--80.5)
  Number of events (n)                                                 656                      123 (53--215)                                                                                            27 (12--57)
  Event rate, %                                                        3.9                      5.7 (5.7--6.1)                                                                                           6.3 (3.0--10.5)
  Sex reported, n (%)                                                  NA                       5 (100%)                                                                                                 50 (68%)
  Men, %                                                               69.1                     65.2 (62.5--66.5)                                                                                        52.5 (46.8--64.1)
  Type of intervention, n (%)                                                                                                                                                                            
  Surgery                                                              1 (100%)                 5 (100%)                                                                                                 52 (71.2%)
  Percutaneous                                                         0 (0%)                   0 (0%)                                                                                                   20 (27.4%)
  Both                                                                 0 (0%)                   0 (0%)                                                                                                   1 (1.4%)
  Valve‐related, %                                                     53.3                     56 (54.6--56.1)                                                                                          100 (100--100)
  Enrollment, y (range)                                                2010                     2005 to 2013                                                                                             1999 to 2015
  C‐statistic                                                          0.8095                   0.82 (0.76--0.85)                                                                                        0.72 (0.67--0.78)
  C‐statistic (range)                                                  NA                       0.737 to 0.861                                                                                           0.50 to 0.95
  Any calibration reported, n (%)                                      0 (0%)                   4 (80%)                                                                                                  65 (89%)
  Change in discrimination,[d](#jah34436-note-0012){ref-type="fn"} %   NA                       2.6 (−16.0--13.1)                                                                                        −28.9 (−45.3--−9.5)

EuroSCORE indicates European System for Cardiac Operative Risk Evaluation.

All values are reported as median (interquartile range) unless otherwise specified.

Validation data is reported at the population level only; patient‐level data was not available.

Validation population are "related" if it meets all of the following criteria: (1) same type of intervention (eg, both surgical populations), (2) ±10% absolute difference in the proportion of isolated valve procedure (eg, derivation population was 100% isolated valve and validation population was 95% isolated valve), and (3) overlapping years of enrollment. A validation population that does not meet all 3 criteria is "distantly related."

Change in discrimination is calculated as \[(Validation AUC−0.5)−(Derivation AUC−0.5)\]/(Derivation AUC−0.5)×100.

###### 

STS (2009) Population Compared With External Validation Populations, Stratified by Relatedness

  Statistic[a](#jah34436-note-0014){ref-type="fn"}                     STS Models (n=9)      Validation Populations[b](#jah34436-note-0015){ref-type="fn"},[c](#jah34436-note-0016){ref-type="fn"}   
  -------------------------------------------------------------------- --------------------- ------------------------------------------------------------------------------------------------------- ----------------------
  Total patients, n                                                    109 759               37 395                                                                                                  49 530
  Total validations, n                                                 NA                    33                                                                                                      37
  Age, y                                                               Not Reported          64.7 (56.6--73)                                                                                         81.6 (74.5--83)
  Number of events, n                                                  9164 (3706--12 892)   29 (12--82)                                                                                             38 (18--57)
  Event rate, %                                                        8.3 (3.4--11.7)       4.9 (2.7--12.6)                                                                                         9.1 (3.7--11.7)
  Men, %                                                               55.4                  56 (56.0--74.9)                                                                                         47.8 (43.6--55.3)
  Type of intervention, n (%)                                                                                                                                                                        
  *Surgery*                                                            9 (100%)              33 (100%)                                                                                               8 (21.6%)
  *Percutaneous*                                                       0 (0%)                0 (0%)                                                                                                  28 (75.7%)
  *Both*                                                               0 (0%)                0 (0%)                                                                                                  1 (2.7%)
  Valve‐related, %                                                     100                   100 (100--100)                                                                                          100 (100--100)
  Enrollment, y (range)                                                2002--2006            1997--2014                                                                                              1999--2015
  C‐statistic, median, IQR                                             0.74 (0.70--0.77)     0.72 (0.67--0.79)                                                                                       0.65 (0.6--0.71)
  C‐statistic (range)                                                  0.643 to 0.805        0.612 to 0.86                                                                                           0.5 to 0.81
  Calibration reported, n (%)                                          9 (100%)              18 (54.5%)                                                                                              28 (75.7%)
  Change in discrimination,[d](#jah34436-note-0017){ref-type="fn"} %   NA                    −21.3 (−34.4--2.3)                                                                                      −50.8 (−67.2--−25.1)

IQR indicates interquartile range; STS, Society of Thoracic Surgeons.

All values are reported as median (interquartile range) unless otherwise specified.

Validation data is reported at the population level only; patient‐level data was not available.

Validation population is "related" if it meets all of the following criteria: (1) same type of intervention (eg, both surgical populations), (2) ±10% absolute difference in the proportion of isolated valve procedure (eg, derivation population was 100% isolated valve and validation population was 95% isolated valve), and (3) overlapping years of enrollment. A validation population that does not meet all 3 criteria is "distantly related."

Change in discrimination is calculated as \[(Validation AUC−0.5)−(Derivation AUC−0.5)\]/(Derivation AUC−0.5)×100.

Of CPMs that have been validated at least 2 times (n=17) in related populations, the highest median validation c‐statistic was seen for EuroSCORE II (0.82 \[IQR, 0.76--0.85\]), followed by the North West Quality Improvement Programme in Cardiac Interventions model (0.78 \[IQR, 0.77--0.78\]), and the Northern New England Aortic model (0.76 \[IQR, 0.75--0.77\]) (Table [6](#jah34436-tbl-0006){ref-type="table"}).

###### 

CPMs that Have Been Validated ≥2 Times in Related Populations

  De Novo CPM   External Validations in Related Populations (n)   Validation C‐statistic, median (IQR)   \% Change in Discrimination,[a](#jah34436-note-0019){ref-type="fn"} Median (IQR)   Any Calibration Reported (%)   
  ------------- ------------------------------------------------- -------------------------------------- ---------------------------------------------------------------------------------- ------------------------------ ------
  2001          STS (original): Isolated Valve                    2                                      0.77 (0.77, 0.77)                                                                  2.6 (2.6--2.6)                 100
  2004          NNE Aortic                                        2                                      0.76 (0.76, 0.77)                                                                  4.0 (2.0--6.0)                 100
  2007          NWQIP                                             2                                      0.78 (0.77, 0.78)                                                                  −1.8 (−2.7--−0.9)              100
  2005          Ambler                                            4                                      0.73 (0.72, 0.76)                                                                  −15.2 (−18.9--−2.2)            100
  2009          STS: Mortality                                    19                                     0.74 (0.71, 0.79)                                                                  −21.3 (−31.5--−4.8)            95
  2009          STS: Stroke                                       2                                      0.65 (0.65, 0.66)                                                                  −20.9 (−23.8--−17.9)           0
  2009          STS: Prolonged Ventilation                        2                                      0.72 (0.68, 0.75)                                                                  −20.2 (−33.8--−6.6)            0
  2009          STS: Prolonged LOS                                2                                      0.67 (0.65, 0.68)                                                                  −38.1 (−43.5--−32.8)           0
  2009          STS: Renal Failure                                2                                      0.76 (0.72, 0.79)                                                                  −9.6 (−22.5--3.4)              0
  2009          STS: DSWI                                         2                                      0.68 (0.65, 0.70)                                                                  −13.7 (−24.8--−2.7)            0
  2009          STS: Composite AEs                                2                                      0.68 (0.65, 0.71)                                                                  −18.8 (−30.7--−6.9)            0
  2009          STS: Reoperation                                  2                                      0.64 (0.63, 0.65)                                                                  −2.1 (−11.9--7.7)              0
  2011          Aus‐AVR Score                                     3                                      0.72 (0.67, 0.72)                                                                  −22.9 (−40.4--−20.4)           100
  2012          EuroSCORE II                                      5                                      0.82 (0.76, 0.85)                                                                  2.6 (−16.0--13.1)              80
  2013          NY Operative Mortality Risk Score                 3                                      0.73 (0.71, 0.75)                                                                  −18.1 (−26.5--−9.8)            66.7
  2014          OBSERVANT Score                                   4                                      0.60 (0.58, 0.61)                                                                  −57.8 (−63.7--50.7)            50
  2014          STT: 30 d                                         2                                      0.66                                                                               0                              50

AEs indicates adverse events; Aus‐AVR, Australian aortic valve replacement; CPM indicates clinical predictive models; DSWI, deep sternal wound infections; EuroSCORE, European System for Cardiac Operative Risk Evaluation; IQR, interquartile range; LOS, length of stay; NNE, Northern New England; NWQIP, North West Quality Improvement Programme in Cardiac Interventions; NY, New York; OBSERVANT, Observational Study of Appropriateness, Efficacy and Effectiveness of AVR‐TAVR Procedures for the Treatment of Severe Symptomatic Aortic Stenosis; STS, Society of Thoracic Surgeons; STT, Survival posT‐TAVI; TAVI, transcatheter aortic valve implantation.

Change in discrimination is calculated as \[(Validation AUC−0.5)−(Derivation AUC−0.5)\]/(Derivation AUC−0.5)×100.

Forty‐five (22%) external validations did not report any measure of calibration. Of the 159 validations that did report calibration, 103 (65%) reported the Hosmer‐Lemeshow statistic, 87 (55%) reported calibration‐in‐the‐large, and 46 (29%) included a calibration plot. Median c‐statistic was 0.71 (IQR, 0.65--0.77) for validations that reported some measure of calibration and 0.68 (IQR, 0.63--0.74) for validations that did not report any calibration.

Clinical relatedness between the development and validation populations was assessed using a novel rubric. Seventy‐one validations (35%) were performed on related populations, while the remaining 133 (65%) were performed on distantly‐related populations. The median validation c‐statistic was 0.73 (IQR, 0.67--0.79) for related validations and 0.70 (IQR, 0.62--0.76) for distantly‐related validations (*P*=0.009). There was a significant difference in percentage change in discrimination: the median change in c‐statistic was −12.2% (IQR, −28.3%--+2.5%) for related validations and −32.1% (IQR, −54.9%--−12.8%) for distantly‐related validations (Figure [2](#jah34436-fig-0002){ref-type="fig"}, *P*\<0.0001).

![Percentage change in discrimination in external validations of valvular heart disease clinical prediction models, stratified by relatedness. Each bar represents a unique external validation that reports a c‐statistic (n=205). Society of Thoracic Surgeons (2009) Models. Percentage change in discrimination is calculated as (\[validation c‐statistic--0.5\]--\[derivation c‐statistic--0.5\])/\[derivation c‐statistic--0.5\]×100. STS indicates Society of Thoracic Surgeons](JAH3-8-e011972-g002){#jah34436-fig-0002}

CPMs that were derived on percutaneously‐treated VHD populations and externally validated (n=9) underwent a total of 19 validations, almost all of which were on percutaneous populations. CPMs that were derived on surgical VHD populations and externally validated (n=25) underwent a total of 184 validations, of which 130 (71%) were on surgical populations, 52 (28%) were on percutaneous populations, and 2 (1%) were on populations including both surgical and percutaneous interventions. For validations of surgical VHD models discrimination was better when CPMs were tested on cohorts treated with surgical versus percutaneous interventions (median c‐statistic 0.74 versus 0.63, *P*\<0.001).

Of the surgical VHD CPMs validated on percutaneous populations (n=52 validations), the CPM most often validated was the STS (2009) model predicting mortality (n=27, median c‐statistic 0.64 \[IQR, 0.58--0.67\]). EuroSCORE II (n=20) had the highest discrimination in this setting, with a median c‐statistic of 0.67 (IQR, 0.55--0.71).

Discussion {#jah34436-sec-0023}
==========

Here we show that there are many CPMs available for patients with VHD and that many of these CPMs have not been externally validated. For the CPMs that have been externally validated, models often perform substantially worse than expected based on performance in derivation data sets. Notably, isolated external validations of VHD CPMs appear insufficient for broadly understanding CPM performance in the context of specific clinical decisions as predictive models may have highly variable performance across various databases. For patients under consideration for surgical VHD interventions, there are CPMs that have been extensively validated. The fidelity of TAVR CPM predictions is largely unknown, as these models have not been widely tested in external validations.

Predicted risk is central to procedural decision making for patients with VHD, however. individual risk estimates using published CPMs for VHD appear more uncertain than originally thought, especially when prediction models are derived on patients who are not closely related to the patients being treated. CPM performance (specifically discrimination) substantially degrades from the derivation population to the validation population, particularly when populations are "distantly related" with respect to procedure type (percutaneous versus open surgical), therapeutic era, and the need for concurrent revascularization. Without attention to these patient‐level specifics, it is likely that there is widespread inappropriate use of CPMs that are informing treatment decisions for patients with VHD. While it is encouraging that newer models have been developed for TAVR patients, these CPMs have not been widely validated or integrated into contemporary guidelines, and have risk estimates that may become inaccurate as devices continue to improve and procedural techniques mature. The attenuated performance of these TAVR CPMs may also be related to the magnitude and significance of comorbid illnesses that are common for older treated adults and are rarely included as part of parsimonious modeling efforts.[45](#jah34436-bib-0045){ref-type="ref"} More work is needed to understand these risk factors.

The decrease in discrimination that is observed in this study may be attributable to model overfitting, differences in case mix (ie, narrower populations in the validation data set), and phenotypic heterogeneity. Ultimately, the relevant performance metrics for clinicians relate to the patients they are treating (with a specific intervention), not to performance measured at the time of CPM development. Rarely, discrimination appears to improve during validations. This is likely the result of differences between the derivation population and the validation population where some models are developed on more highly selected (narrow case‐mix) cohorts than they are testing on. The data presented here demonstrates that CPMs externally validated multiple times show substantial variation in performance. This strongly suggests that adequate performance demonstrated in a single external validation may be insufficient to assess the quality (and utility) of VHD CPMs and that a more tailored approach is needed to understand the trustworthiness of CPM predictions in specific settings.

There is increasing recognition of the central importance of CPM calibration. Surprisingly, calibration was reported in only 78% of the external validations of VHD CPMs. There is no agreed‐upon standard for reporting model calibration and no consensus on interpreting this metric. Moreover, there are well‐recognized limitations to the most commonly reported measure, the Hosmer‐Lemeshow statistic (eg, sample‐size dependence).[46](#jah34436-bib-0046){ref-type="ref"} Reporting of model calibration represents a major shortcoming in the assessment and overall trustworthiness of VHD CPMs, as adequate calibration can protect against harm.[13](#jah34436-bib-0013){ref-type="ref"} Ongoing efforts, including the Transparent Reporting of a Multivariable Model for Individual Prognosis or Diagnosis statement[47](#jah34436-bib-0047){ref-type="ref"} and the Prognosis Research Strategy,[48](#jah34436-bib-0048){ref-type="ref"} should lead to more consistent evaluation and better reporting of this important performance metric. For currently available CPMs, it is important for clinicians to know whether predictions over‐ or underestimate risk when compared with observed event rates in similar patients, especially when the decision for or against a particular intervention is informed by this output (as is the case for percutaneous VHD treatments). Poor calibration can often be overcome with a variety of updating techniques that can substantially improve accuracy of predictions.[49](#jah34436-bib-0049){ref-type="ref"}

There is much that remains unknown about these predictive models. CPM performance has not been studied for patients treated in many areas of Eastern Europe, Asia, Central America, South America, and Africa. This is especially important considering the many regional differences in VHD etiology, access to technologies, care systems, and guidelines.[50](#jah34436-bib-0050){ref-type="ref"}, [51](#jah34436-bib-0051){ref-type="ref"}, [52](#jah34436-bib-0052){ref-type="ref"} The optimal number of validations required to adequately assess CPM performance remains unknown. Ideally, CPMs are serially validated and recalibrated (if necessary) to optimize performance for specific, local clinical decision making. Without addressing these limitations, clinical decisions that leverage CPM outputs may be inaccurate and lead to harmful decisions.

This analysis offers a structure to consider which CPMs are most accurate (discrimination and calibration) and trustworthy (consistent performance in multiple external validations). For patients being considered for surgical valve interventions, EuroSCORE II (median validation c‐statistic 0.82 \[0.76, 0.85\]), North West Quality Improvement Programme in Cardiac Interventions Model (median validation c‐statistic 0.78 \[0.77, 0.78\]), Northern New England Aortic Model (median validation c‐statistic 0.76 \[0.76, 0.77\]), Ambler (median validation c‐statistic 0.73 \[0.72, 0.76\]), and STS (2009) Mortality (median validation c‐statistic 0.74 \[0.71, 0.79\]) have reasonable discrimination and multiple assessments of discrimination and calibration in external data sets. There are no CPMs for patients treated with TAVR that demonstrate good performance across multiple related validation databases. The trustworthiness of these newer risk estimates for TAVR remains under‐studied.

There are several limitations to this work. Our review was limited to CPMs that provide enough information in the published report to calculate a risk prediction for a patient. Logistic regression models that did not report a full equation or intercept were not included. Cox regression models that did not report a point score or baseline hazard were excluded. The search for de novo VHD CPMs was last run in January 2017. While newer CPMs have been developed, there is often substantial delay before the publication of subsequent external validations. Notably, we present relative changes in discrimination to more accurately document changes on a clinically relevant scale, where small decreases in the C‐statistic can result in large changes in clinically relevant performance. Lastly, this study was limited in its examination of CPM calibration, which is an important measure of model performance, but often poorly reported and without a widely‐accepted summary measure.

While there are numerous available CPMs for patients with VHD, many have never been externally validated, and for those that have, discriminatory performance is often much worse than originally reported. We note that CPM performance is highly dependent on the cohort selected for study, suggesting that one‐off external validations may inadequately assess performance. Instead of new CPM development, robust external validations of established TAVR CPMs and an understanding of the updating techniques that best optimize model performance are needed.
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